Related Experiment Videos
Granulocyte/macrophage progenitor cells from peripheral blood and bone marrow differ in their response to
1Department of Medicine, Rush Medical College, University of Chicago, IL.
Abstract:
Prostaglandins of the E series (PGE) inhibit proliferation of normal bone marrow granulocyte/macrophage progenitors (CFU-GM). Circulating CFU-GM are known to differ from marrow CFU-GM in many characteristics, and in the present study, we compared the effect of PGE1 on circulating and bone marrow progenitors in normals and in patients with chronic myelogenous leukemia (CML). PGE1 caused a dose-dependent inhibition of normal marrow CFU-GM. Circulating CFU-GM were inhibited only at concentrations of 10(-5) mol/L or greater, and progenitor proliferation was, in fact, significantly stimulated at PGE1 concentrations between 10(-8) and 10(-6) mol/L. Bone marrow CFU-GM from patients with CML were inhibited in a manner similar to that of normal bone marrow. Circulating cells from patients with CML were, however, less sensitive to PGE1 inhibition than CML bone marrow cells and demonstrated a pattern intermediate between normal circulating and normal marrow progenitors. These studies suggest that peripheral blood and bone marrow contain different progenitor cell populations.
Insights
Prostaglandins E1 (PGE1) differentially affect normal and chronic myelogenous leukemia (CML) progenitor cells. Circulating progenitors are less sensitive to PGE1 inhibition than bone marrow progenitors, suggesting distinct cell populations.
Area of Science:
- Hematology
- Cell Biology
- Oncology
Background:
- Prostaglandins E series (PGE) are known to inhibit normal bone marrow granulocyte/macrophage progenitors (CFU-GM).
- Circulating CFU-GM exhibit distinct characteristics compared to bone marrow CFU-GM.
Purpose of the Study:
- To compare the effects of Prostaglandin E1 (PGE1) on circulating and bone marrow progenitor cells.
- To investigate these effects in both healthy individuals and patients with chronic myelogenous leukemia (CML).
Main Methods:
- Dose-dependent inhibition assays were performed using PGE1.
- Progenitor cell proliferation was assessed in normal individuals and CML patients.
- Comparisons were made between bone marrow and circulating progenitor cells.
Main Results:
- PGE1 inhibited normal bone marrow CFU-GM in a dose-dependent manner.
- Circulating normal CFU-GM showed inhibition only at high PGE1 concentrations (≥10(-5) mol/L) and stimulation at lower concentrations (10(-8) to 10(-6) mol/L).
- CML bone marrow CFU-GM responded similarly to normal bone marrow CFU-GM, while CML circulating cells were less sensitive to PGE1 inhibition than CML bone marrow cells.
Conclusions:
- Peripheral blood and bone marrow contain distinct progenitor cell populations with differential responses to PGE1.
- These findings contribute to understanding hematopoiesis regulation in normal and malignant conditions.
- The differential sensitivity of progenitors may have implications for CML pathogenesis and treatment.